The global anti-inflammatory biologics market size is expected to reach USD 149.80 billion by 2027, exhibiting a CAGR of 11.0% during the forecast period. The indication of an inflammatory surplus in patients with COVID-19 along with plentiful neutrophils and macrophages will revivify growth prospects for the anti-inflammatory biologics market share during the forecast period. The ongoing trials for anti-tumor necrosis factor (TNF) antibodies in severe cases of autoimmune inflammatory disease such as rheumatoid arthritis, inflammatory bowel disease, or ankylosing spondylitis will aid the speedy expansion of the market during the forecast period, mentioned by Fortune Business Insights, in a report, titled “Anti-Inflammatory Biologics Market Size, Share & Industry Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection (Subcutaneous and Intravenous)), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027” the market size stood at USD 64.84 billion in 2019.

Please visit:https://www.fortunebusinessinsights.com/anti-inflammatory-biologics...